Mallinck­rodt preps a pos­si­ble bank­rupt­cy amid a mael­strom of opi­oid claims — re­port

Strug­gling with $5 bil­lion in debt and a mael­strom of le­gal claims over their al­leged role in a na­tion­wide epi­dem­ic of opi­oid abuse, Mallinck­rodt has re­port­ed­ly been con­sult­ing with lawyers and re­struc­tur­ing pros to see if they should re­struc­ture the com­pa­ny in bank­rupt­cy.

Bloomberg re­port­ed that the bio­phar­ma com­pa­ny — fre­quent­ly fin­gered as one of the worst play­ers in­volved in price goug­ing — has hired Lath­am & Watkins along with Al­ix­Part­ners to ex­plore their op­tions. And that trig­gered a rout as in­vestors fled the stock $MNK, send­ing its shares down 44% af­ter the bell.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER